Drug Manufacturers - Specialty & Generic

Rising prevalence of diabetes, cardiovascular disease, and obesity is structurally expanding the addressable market for chronic-care medicines in India. Cardiac, anti-diabetes, and pain therapy segments are already demonstrating resilient value growth, with GLP-1 drugs such as semaglutide emerging as a new high-growth category. This demographic and epidemiological shift supports durable volume and value growth for manufacturers with strong chronic-therapy portfolios.

The Indian government's Biopharma Shakti Mission and associated R&D deregulation initiatives are designed to redirect investment from commodity generics toward innovative and biopharmaceutical capabilities. Simplified regulatory processes, AI-assisted drug development tools, and removal of protocol-study permissions are expected to reduce time-to-market and development costs. Over a five-year horizon, these reforms could materially improve the innovation pipeline and margin profile of leading Indian manufacturers.

The ten largest pharmaceutical companies in India are consistently outperforming smaller rivals on volume growth, reflecting structural advantages in brand equity, distribution reach, and chronic-therapy depth. This consolidation dynamic is likely to persist as scale becomes increasingly important for navigating regulatory complexity and funding R&D. Larger manufacturers are better positioned to absorb competitive and pricing pressures while capturing disproportionate share of market growth.

India's domestic pharma market is projected to grow 9–11%, with export demand providing an additional growth vector as global healthcare systems seek cost-effective generic supply. India's established manufacturing infrastructure and regulatory track record with agencies such as the US FDA and EMA underpin its role as a preferred generics supplier. Strengthening export pipelines support revenue diversification and reduce dependence on any single market.

The expiry of key semaglutide patents has enabled seventeen Indian companies to launch generic GLP-1 therapies, creating a rapidly expanding new category within the domestic market. Generic GLP-1 launches are contributing materially to overall pharma market growth and expanding patient access to diabetes and obesity treatments. This category is expected to grow significantly as awareness increases and pricing becomes more accessible across income segments.

Potential US tariffs of 100% on generic drug imports from August 2028, escalating to 200% from August 2029, represent a significant medium-term risk for Indian manufacturers with material US revenue exposure. If implemented, these tariffs could compress margins, force pricing renegotiations, and reduce competitiveness against domestically manufactured US generics. The uncertainty itself may dampen investment in US-facing capacity and pipeline development in the near term.

The rapid entry of seventeen companies into the generic semaglutide market illustrates the speed with which Indian manufacturers commoditise newly genericised molecules, compressing unit economics. Smaller and mid-tier manufacturers face particular pressure as larger players leverage scale and brand to defend margins in a crowded competitive landscape. Sustained price erosion in high-volume generic categories could offset volume growth benefits at the revenue and margin level.

Despite 10.7% year-on-year value growth in August 2026, volume growth remained modest at 1.1%, indicating that market expansion is being driven primarily by price and mix rather than broad-based volume increases. This divergence suggests underlying demand elasticity constraints and potential affordability barriers that could limit the sustainability of high value-growth rates. If pricing power moderates, overall market growth could decelerate without a corresponding pickup in volumes.

The ongoing consolidation of market share toward larger manufacturers is leaving smaller companies exposed to uneven demand, weaker distribution, and limited ability to invest in chronic-therapy or innovative pipelines. Smaller generics manufacturers face compounding headwinds from regulatory compliance costs, price controls, and competition from well-capitalised peers. This structural polarisation may accelerate consolidation but also creates near-term earnings risk across the broader sector.

While the government's proposed digital regulation, AI-assisted approvals, and deregulation measures are directionally positive, their implementation timelines and scope remain uncertain. Delays or partial execution of the Biopharma Shakti Mission and associated incentives could slow the sector's transition toward higher-value manufacturing. Regulatory reform in pharmaceuticals is complex and subject to political and administrative friction that may extend the realisation horizon for anticipated benefits.